Tens of thousands of patients in the US alone are diagnosed with CUP each year. Many of these patients undergo a wide range of costly, time-consuming, and inefficient tests to try to find out where their cancer started¹. However, the primary origin of the cancer is never identified².

Many of the tests currently used to identify the primary origin of CUP are inadequate.1 miRview® mets is a different kind of test. It uses cutting-edge technology as well as recently discovered and highly accurate biomarkers to identify the primary site.

To determine your best course of treatment, your doctor needs to know where your cancer started. In most cases, miRview® mets can provide answers. And that can help ensure that you start on the right treatment right away.

1. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer.
   Cancer. 2004;100(9):1776-1785.
2. Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary: clinicopathologic correlations.
   APMIS. 2003;111(12):1089-1094.